arrow
F

Francesco Pepe

department of public health
H指数:29
被引数:2,724

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Dynamic Role of Liquid Biopsy in Patients with Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: Emerging Opportunities and Clinical Challenges

液体活检在非小细胞肺癌患者接受免疫检查点抑制剂治疗中的动态作用:新兴机遇与临床挑战

Cancers
IF4.4
2026-10-090
OA
Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation

肺癌中循环游离DNA的表观遗传学分析用于早期检测和微小残留病评估:聚焦DNA甲基化

2026-08-310
OA
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2-breast cancer after progression on CDK4/6 inhibitor therapy

在HR+/HER2-乳腺癌患者对CDK4/6抑制剂治疗进展后,对来自转移灶的FFPE样本进行ESR1基因检测

2025-05-140
OA
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery

整合临床-分子数据以预测接受间隔肿瘤细胞减灭术的晚期卵巢癌患者对PARP抑制剂的疗效

2025-04-010
OAAI
BRCA testing in metastatic castration-resistant prostate cancer: successes and troubles in a real world setting. An Italian Multicentric study
2024-10-010
OA
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy
2024-10-010
OA
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

根据BRCA结构域突变和突变类型,PARP抑制剂在晚期高级别浆液性卵巢癌中的疗效

2024-09-093
OAAI
Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer
2024-03-220
PRE